Summary
The only label-relevant claims (thyroid C-cell tumors, contraindication in MTC/MEN 2, and uncertain value of routine calcitonin/ultrasound monitoring) are supported by the provided FDA label excerpts (Boxed Warning, 4, 5.1, 13.1). Other provided user claims are outside the provided label excerpts and cannot be evaluated against the supplied text.
Category Scores
Accurate Statements
Semaglutide causes thyroid C-cell tumors in rodents and its relevance to humans is unknown.
Supported by Boxed Warning; Warnings and Precautions (5.1); Nonclinical Toxicology (13.1).
Ozempic is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or with MEN 2.
Supported by Contraindications (4); repeated in Boxed Warning and Warnings and Precautions (5.1).
Routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Ozempic.
Supported by Warnings and Precautions (5.1).
Unsupported Statements
Metformin decreases glucose production in the liver.
Not supported or contradicted by the provided FDA label excerpts (which focus on thyroid C-cell tumor risk/contraindication).
Metformin increases insulin sensitivity.
Not supported or contradicted by the provided FDA label excerpts.
The combination of semaglutide and metformin may increase the risk of hypoglycemia (low blood sugar) in patients with type 2 diabetes.
Not supported or contradicted by the provided FDA label excerpts.
The risk of hypoglycemia is higher when semaglutide is used in combination with metformin compared to using either medication alone.
Not supported or contradicted by the provided FDA label excerpts.
Dose adjustments may be necessary in patients who experience hypoglycemia while taking semaglutide and metformin.
Not supported or contradicted by the provided FDA label excerpts.
Patients with a history of hypoglycemia may require dose adjustments when taking the combination of Ozempic and metformin.
Not supported or contradicted by the provided FDA label excerpts.
The dose of Ozempic may need to be adjusted based on the patient's response to the medication.
Not supported or contradicted by the provided FDA label excerpts.
The dose of metformin may need to be adjusted based on the patient's response to the medication.
Not supported or contradicted by the provided FDA label excerpts.
Patients taking other medications that may interact with Ozempic or metformin may require dose adjustments.
Not supported or contradicted by the provided FDA label excerpts.
The recommended dose of Ozempic when used in combination with metformin is 0.5 mg or 1 mg once weekly.
Not supported or contradicted by the provided FDA label excerpts.
The recommended dose of metformin when used in combination with Ozempic is 500 mg or 1000 mg twice daily.
Not supported or contradicted by the provided FDA label excerpts.
Patients taking the combination of Ozempic and metformin should monitor their blood sugar levels regularly to prevent hypoglycemia.
Not supported or contradicted by the provided FDA label excerpts.
Ozempic (semaglutide) is a GLP-1 receptor agonist used to improve glycemic control in patients with type 2 diabetes.
Not supported or contradicted by the provided FDA label excerpts (thyroid C-cell tumor risk sections only).
Ozempic (semaglutide) reduces the risk of major adverse cardiovascular events in patients with type 2 diabetes.
Not supported or contradicted by the provided FDA label excerpts.
Semaglutide is used to counsel patients regarding the potential risk for MTC and inform them of symptoms of thyroid tumors (e.g., mass in the neck, dysphagia, dyspnea, persistent hoarseness).
While the supporting label text is present in the provided excerpts, this specific counseling/symptom content was not included as an explicit claim in the supplied evaluation claims; therefore it cannot be verified against the AI response content beyond what was stated in the label-citation audit.
Contradictions
Important Omissions
If the AI response claimed only thyroid-related content, no other major omissions can be assessed because the provided FDA excerpts cover only Boxed Warning/5.1/4/13.1.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The only statements evaluated against the provided label excerpts (thyroid C-cell tumors in rodents with unknown human relevance; contraindication in MTC/MEN 2; uncertain value of routine calcitonin/thyroid ultrasound monitoring) were consistent with the label.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several non-thyroid claims in the provided set (e.g., metformin mechanism, hypoglycemia risk comparisons, dosing specifics, drug interactions, and monitoring frequency) cannot be confirmed against the supplied FDA label excerpts focused on thyroid C-cell tumors/contraindication.
Suggested Improvement
Limit evaluated claims to the label sections provided (Boxed Warning, Contraindications 4, Warnings/Precautions 5.1, and Nonclinical Toxicology 13.1) or supply additional label excerpts for dosing/interactions/hypoglycemia to enable accurate alignment checking.